Revon Media
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
Revon Media
No Result
View All Result

Johnson & Johnson completes acquisition of Abiomed

Johnson & Johnson completes acquisition of Abiomed
Share on FacebookShare on Twitter

Johnson & Johnson, the world’s largest, most diversified healthcare products company, announced on Dec 22, 2022, it has completed its acquisition of Abiomed Inc.

As part of Johnson & Johnson, Abiomed will operate as a standalone business within Johnson & Johnson’s MedTech segment.

“We are excited to officially welcome the talented Abiomed team to Johnson & Johnson. Their patient-first philosophy aligns with Our Credo and Our Purpose to change the future of health for humanity,” said Joaquin Duato, CEO of Johnson & Johnson.

“This acquisition marks another important step on Johnson & Johnson’s path to accelerating growth in our MedTech business and delivering innovative medical technologies to more people around the world.”

Ashley McEvoy, Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson, added: “The completion of this acquisition allows Johnson & Johnson MedTech to expand our portfolio in the high growth cardiovascular markets, adding solutions for heart recovery to our global market leading Biosense Webster electrophysiology business.

“Fueled by Johnson & Johnson’s global scale and commercial and clinical strength, we are excited to explore the opportunities and possibilities ahead to reach even more patients with critical unmet need.”

Johnson & Johnson’s tender offer for all outstanding shares of Abiomed for an upfront payment of US$380 per share in cash, corresponding to an enterprise value of approximately US$16.6 billion, which includes cash acquired, expired at 11:59 p.m., New York City time, on Dec 21, 2022.

Abiomed shareholders will also receive a non-tradeable contingent value right (“CVR”) entitling the holder to receive up to US$35.00 per share in cash if certain commercial and clinical milestones are achieved.

American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has advised Johnson & Johnson that approximately 25,759,195 shares of Abiomed common stock were validly tendered and not properly withdrawn in the tender offer, representing approximately 57.1 per cent of the then-outstanding shares of Abiomed’s common stock.

In connection with the completion of the transaction, Abiomed’s common stock ceased trading on NASDAQ. – The Health

Tags: Abiomed IncAcquisitionForeign NewsJohnson & JohnsonThe Health 2023The Health Jan/Feb 2023theHealth
Previous Post

Organ damage risk for lupus patients

Next Post

Indonesia’s leading plant-based food tech start-up launched

Live Edition Paper

NOV 2020 ePaper

OCT 2020 ePaper


 

Subscribe for free complimentary live editions:

Recent News

  • My Covid experience
    September 30, 2021
    Early testing may help prevent being inadvertently injured by possible and […]
  • Duopharma distributes Sinopharm vaccines
    November 29, 2021
    DUOPHARMA Biotech Berhad has further strengthened Malaysia’s Covid-19 […]
  • Am I losing my sight? My power keeps increasing
    October 6, 2021
    Myopia can progressively worsen to a higher power, so it is best to get your […]
  • MoH starts Ivermectin trial
    October 6, 2021
    On June 5, Dr Noor Hisham announced the MoH had begun Ivermectin trials for […]
  • IJN addresses medication non-adherence
    August 16, 2022
    The National Heart Institute or Institut Jantung Negara (IJN) has embarked on […]

Connect

Office

Revon Media Sdn Bhd
A member of Revongen Corporation
Headquarters
Revongen Corporation Center,
Level 17, Top Glove Tower, No.16,
Persiaran Setia Dagang,Setia Alam,
Seksyen U13, 40170 Shah Alam,
Selangor Darul Ehsan, Malaysia.

Contact

Tel: +603 3359 1166
Fax: +6 03 3358 0303

Copyright © 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd. About Us | Contact Us | Privacy Policy | Terms of use

No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us

© 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist